Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today we highlight:
- an article analyzing the “possible outcomes . . . and the downstream impact of the Supreme Court decision” in President Trump’s tariffs case;
- a commentary discussing how the Supreme Court’s intervention in the “skinny label” patent case “has drawn immediate attention from pharmaceutical companies and their counsel”;
- a blog post arguing “it is time for the Supreme Court to step in and provide a definition and workable test for the abstract-ideas exclusion”; and
- an article addressing whether “the U.S. patent system has shown measurable signs of becoming more favorable to patent owners, particularly in the context of post-grant proceedings such as inter partes review . . . and post-grant review.”
